Exclusive: Khosla Ventures leads seed round in mRNA biotech looking to reverse aging by lengthening telomeres
A tiny biotech startup called Rejuvenation Technologies is the latest to chase a massive ambition in reversing aging, a buzzy and often controversial research area emerging in biotech.
Rejuvenation announced Wednesday it has raised $10.6 million in a seed round led by Khosla Ventures. The California startup, founded by two Stanford PhD scientists, believes now is the right time to develop drugs that lengthen telomeres, which act like protective caps on the ends of chromosomes. The field has experienced plenty of ups and downs over the last couple of decades. No biotech has yet to successfully develop a drug targeting these DNA sequences.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.